Sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists have emerged as the drugs of choice for patients with DKD due to their proven benefits beyond glycemic control. The gene discussed is GLP1R; the disease is diabetic kidney disease.